Y0002236

Sorafenib for peak identification

European Pharmacopoeia (EP) Reference Standard

• 別名: Sorafenib tosylate, 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate, BAY 43-9006 tosylate salt, BAY43-9006 tosylate salt, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, 4-methylbenzenesulfonate
• 実験式（ヒル表記法）: C₂₁H₁₆ClF₃N₄O₃·C₇H₈SO₃
• CAS番号: 475207-59-1
• 分子量: 637.03
• MDL番号: MFCD08235032
• UNSPSCコード: 41116107
• NACRES: NA.24

特性

• APIファミリー: sorafenib
• メーカー／製品名: EDQM
• 保管温度: 2-8°C
• SMILES記法: FC(F)(F)c2c(ccc(c2)NC(=O)Nc3ccc(cc3)Oc4cc(ncc4)C(=O)NC)Cl.[S](=O)(=O)([O-])c1ccc(cc1)C.[H+]
• InChI: 1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
• InChI Key: IVDHYUQIDRJSTI-UHFFFAOYSA-N

詳細

詳細

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

アプリケーション

Sorafenib for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生物化学的／生理学的作用

Orally active kinase inhibitor that exerts anticancer efficacy via targeting Raf-1 (c-Raf), b-Raf, VEGFR-2 (Flk-1, KDR), VEGFR-3, PDGFR-β, Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Tosylate salt of the orally active kinase inhibitor Sorafenib (BAY 43-9006) that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

その他情報

Sales restrictions may apply.

安全性情報

• ピクトグラム: GHS08,GHS09
• シグナルワード: Danger
• 危険有害性情報: H360FD,H362,H372,H410
• 注意書き: P201 - P202 - P260 - P263 - P273 - P308 + P313
• 危険有害性の分類: Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
• 保管分類コード: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable